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during the last month of treatment. RESULTS: Of 167 patients
(20 men, 147 women; mean age 43.5 years) included in the
analysis, 72% responded to tegaserod. At baseline, SF-36 scores
from IBS-C patients were lower than those from the general pop-
ulation, but increased in all dimensions with treatment (p =
0.0068 for General Health), reaching values similar to those of
the general population. An increase in all SF-36 dimensions was
observed in responders (R), whereas a decrease occurred in non-
responders (NR, General Health dimension p = 0.004). IBS-QOL
scores (from baseline to treatment) signiﬁcantly increased in all
dimensions (p < 0.0001 for overall assessment). The mean incre-
ment in IBS-QOL was greater for R than NR (Overall dimen-
sion, p < 0.05). Upon treatment withdrawal, some dimensions
of SF-36 and IBS-QOL scores decreased but did not return to
pretreatment levels. CONCLUSIONS: QoL is impaired in IBS-C
patients. Treatment with tegaserod 6mg b.i.d. improves QoL in
patients with IBS-C to a level almost equivalent to that of the
general population, and deterioration in QoL occurs upon treat-
ment discontinuation.
METHODS & CONCEPTS
PMC1
USE OF THRESHOLDS FOR SAFETY REPORTING IN 
CLINICAL TRIALS
Frame D, Fahrbach K, Reynolds MW, Ross SD
MetaWorks Inc, Medford, MA, USA
OBJECTIVE: To assess completeness of safety reporting in pub-
lished clinical trials, including use of incidence, severity, and rela-
tionship to drug thresholds for listing of speciﬁc adverse events
(AEs). METHODS: We used data from previously conducted
systematic reviews in three areas: treatment of rheumatoid
arthritis (RA) with disease-modifying anti-rheumatic drugs (168
studies, 1969–2001); treatment of migraine with 5HT-1 agonists
(38 studies, 1991–2003); and anti-neoplastic treatment of
relapsed or refractory non-Hodgkin’s lymphoma (NHL) (27
studies, 1991–2003). The type of safety reporting for each study
was appraised by two reviewers. RESULTS: Only a minority of
studies in each of the clinical areas presented a complete listing
of all AEs occuring during the trial (RA 17%, migraine 8%,
NHL 30%); a substantial number (10–25%) had no safety data
extractable. Among studies with partial AE reporting the thresh-
olds used varied by clinical setting: two-thirds of RA and NHL
studies with a reporting threshold used the author- or investiga-
tor-attributed relationship to drug to determine which AEs
would be listed in published reports, while 71% of migraine
studies with a threshold used incidence (e.g. only AEs occuring
in more than 5% of patients were listed). The severity threshold
(reporting of only serious AEs or only grade 3–4 AEs) was the
least common in all three clinical areas examined. No consistent
relationship was found between complete AE reporting and
study sponsorship (industry vs. non-industry/not reported) or
year published (pre vs. post 1995). Smaller studies (<100
patients) were more likely to contain complete AE reporting,
perhaps due to the difﬁculty of providing a comprehensive listing
of all events in larger studies. CONCLUSIONS: Incidence and
relationship to drug remain common thresholds for AE report-
ing in published clinical trials. Early detection of rare or unan-
ticipated events by meta-analysis of published trial data is thus
made more challenging.
PMC2
A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF
GENETIC TESTING TECHNOLOGIES
Ramsey S1, Henrikson N2, Carlson J2,Veenstra DL2
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA;
2University of Washington, Seattle, WA, USA
Genetic test technologies offer hope for early diagnosis and iden-
tiﬁcation of persons at risk for serious diseases. Because many of
these tests are costly and applicable to large populations, evalu-
ations of the cost-effectiveness of these technologies are impor-
tant. OBJECTIVES: To conduct a systematic search for and
review of economic evaluations of genetic testing technologies.
METHODS: PubMed, Proquest, LexisNexis, Expanded 
Academic Index, The Harvard Review of Economic Analyses,
PsyclINFO, NICE and CCOHTA databases were searched for
original cost-effectiveness articles published from 1990 to
present. MESH terms included: economic(s) and/or cost(s),
genetic, gene, and/or genotype. Selection criteria included genetic
tests for genetic conditions, deﬁned as analysis of human DNA,
RNA, chromosomes, proteins, and certain metabolites in order
to detect heritable disease-related genotypes, mutations, pheno-
types or karyotypes for clinical purposes. Articles were catego-
rized by clinical category and type of economic study (e.g.,
cost-utility, cost-beneﬁt), then graded independently by the
authors using CEA study quality system developed by Chiou et
al (Med Care, 2003;41:32). RESULTS: A total of 149 abstracts
were retrieved using the search terms; 63 met selection criteria.
Types of economic studies were as follows, cost-utility (25%);
cost-beneﬁt (19%); cost-minimization (6%); cost-effectiveness
(59%). Clinical testing categories were as follows: preconception
carrier (8%); prenatal diagnosis (40%); adult (57%). The studies
involved 26 different medical conditions. Study quality ranged
from 43–100 (average 82). Cost-utility studies were of highest
quality (mean 91); cost-minimization studies were of lowest
quality (mean 63). Adult studies had the highest rating (mean
86); preconception testing studies were lowest in quality (mean
74). Intraclass correlation among raters was 0.82 (CI 0.70–0.89).
CONCLUSIONS: A number of economic analyses have been
published in human genetics across a wide range of conditions.
Study quality varied widely. Priority areas for the ﬁeld include
increasing quality and uniformity of measures of outcome.
PMC3
INTRODUCTION OF BIAS WHEN USING THE SMEARING 
RE-TRANSFORMATION METHOD IN THE PRESENCE OF
POSITIVELY SKEWED ANTI-LOGGED RESIDUALS
Wang MT, Malone DC, Skrepnek GH,Armstrong EP
University of Arizona College of Pharmacy,Tucson, AZ, USA
OBJECTIVES: The purpose of this study was to evaluate the
effects of using Duan’s mean anti-logged residuals (mean smear-
ing estimator) or a median smearing estimator with positively
skewed distributions on predicting costs. METHODS: Data for
this study came from managed care pharmacy and medical
records containing drug-drug interactions (DDIs) from January
1, 1997 to December 31, 1999. Two matched cohort groups
were studied. DDI cases were identiﬁed as receiving medications
involving monoamine oxidase inhibitor (MAOIs) or anti-
coagulant DDIs. Controls were age and sex matched to cases.
Costs were positively skewed and were then natural log trans-
formed as the dependent variable in regression models. The
retransformed costs employing the mean and median smearing
estimators, respectively, were compared. Model ﬁt was assessed
using mean squared error (MSE) for both mean and median
smearing estimators. RESULTS: A total of 156 and 5754 sub-
jects were identiﬁed as MAOI and anti-coagulant groups, respec-
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tively. The anti-logged residuals of MAOI group were positively
skewed (skewness = 11.71). MAOI cases had greater costs than
controls ($3866) when the mean smearing estimator was used.
However, employing the median smearing estimator decreased
cost difference to $385, and provided a better model ﬁt (mean:
MSE = 3.80 ¥ 108; median: MSE = 1.19 ¥ 107). For modeling
costs of anti-coagulant DDI cohorts, skewness of anti-logged
residuals in controls was 28.44 as compared to 11.60 for cases.
Consequently, retransformed costs of controls were exaggerated
and had greater expenditures by $6674 when the mean smear-
ing estimator was employed. Conversely, using the median
smearing estimator, cases had greater costs by $216, and the
model ﬁt was better (mean: MSE = 3.04 ¥ 108; median: MSE =
2.41 ¥ 107). CONCLUSION: In this study, employment of the
median instead of the mean smearing estimator provided a better
ﬁtting model and was more accurate in predicting expenditures.
The results also suggest researchers should examine the distrib-
ution of anti-logged residuals when using the smearing 
retransformation.
PMC4
THE USE OF A LIFE ANNUITY TO MORE ACCURATELY
CALCULATE MEDICAL COSTS IN A 
COST-EFFECTIVENESS ANALYSIS
Van Den Bos J
Milliman, Denver, CO, USA
OBJECTIVES: To demonstrate how to use a life annuity to 
calculate medical costs for a cost-effectiveness analysis, and why
researchers should use this method. METHOD: A cost-
effectiveness analysis typically requires a single value to repre-
sent annual medical costs over time. While a straight average of
claims over several years of claims data seems to be a common
method to obtain this estimate, the value needed for the analy-
sis is more accurately calculated using the actuarial concept of a
life annuity. A life annuity is a series of payments (or costs) made
at equal intervals while a given life survives. The researcher cre-
ating a model that includes future annual medical claims needs
to take into account both the future value of the claim dollars
with discounting, and the likelihood that a person will live to
need medical claims each year with the probability of survival.
Once this “annuitized” claim cost is created, it is ready to be
used in a model where the relevant factors—discounting and sur-
vival—are present. This presentation will demonstrate the how
to calculate an annuitized claim cost using medical claims data
from MedStat’s MarketScan database. RESULTS: This demon-
stration will show proper use of discounting, survivorship, and
exposure in the calculation of this value. CONCLUSIONS: This
will be followed by several simpliﬁed models to show how the
resulting annuitized claim cost behaves in a cost-effectiveness
model compared to an actual stream of claim costs, and com-
pared to a claim cost based on a straight average of claims.
PMC5
PERSONNEL COSTS, LEARNING CURVES,
AND SCALE ECONOMIES FOR TELEPHONE-BASED 
NURSE INTERVENTIONS
Grant W, Reed S, Bosworth H, Neary A, Schulman K
Duke University, Durham, NC, USA
OBJECTIVE: For most telephone-based nurse interventions, the
assumption of constant marginal and average personnel costs is
unrealistic. In spite of this fact, researchers frequently report
nursing personnel costs as simple functions of wage rates and
hours worked. In order to better forecast personnel costs, it is
necessary to understand learning and scale effects involving the
cumulative volumes of questions, encounters, and patients. For
an ongoing telephonic blood pressure intervention, we provide
summary statistics and regression output concerning learning
curve effects and economies of scale. METHODS: Using data on
personnel costs and cumulative production from the intervention
“Take Control of Your Blood Pressure,” we obtain least squares
estimates for learning curve elasticities. We include separate
terms in our regression to identify the elasticities of unit costs
with respect to 1) the cumulative volume of patient-speciﬁc
encounters; 2) the cumulative volume of speciﬁc questions; and
3) the cumulative volume of speciﬁc questions for speciﬁc
patients. In addition, we assess alternative returns-to-scale based
on Nerlove’s classic method. RESULTS: The elasticity of per-
sonnel cost is signiﬁcantly negative with respect to the cumula-
tive volume of speciﬁc questions (p = 0.036), and with respect
to the patient-speciﬁc cumulative volume of speciﬁc questions (p
= 0.001). Regarding patient-speciﬁc encounters, there is mixed
evidence concerning learning curve effects and economies of
scale. CONCLUSION: To forecast personnel costs in telephone-
based nursing interventions, it is important to account for learn-
ing curve effects. Including only wage rates and patient grand
means will result in an overestimation of costs. To a signiﬁcant
extent, unit costs decline systematically as cumulative output
rises.
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ACCURATE AND RAPID PREDICTION OF DRUG PLAN
EXPENDITURE WHILE PLANNING REIMBURSEMENT
CHANGES USING POLICY SIMULATION
Dormuth CR1, Burnett S2, Schneeweiss SM1
1Harvard University, Boston, MA, USA; 2Pﬁa Corporation,Victoria, BC,
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Drug plan decision makers need accurate ﬁnancial impact pro-
jections for planning new drug policies. Projections should have
minimal margins of error and be transparent and easy to com-
municate to stakeholders. OBJECTIVES: We explain how ad hoc
methods typically used for ﬁnancial impact projections are inad-
equate. METHODS: We describe a ﬂexible tool for projecting
the ﬁnancial impact of drug policy changes based on historical
dispensing data. The tool uses a random sample of a drug plan’s
beneﬁciaries to simulate the drug claim adjudication process
under the proposed policy regulations. We explore the validity
of the simulation tool using a recent example of a complex drug
policy change in British Columbia (BC). Over 500 different
policy options were simulated in the planning phase of the BC
policy. Drug plan spending was projected for each option before
the ﬁnal policy was selected two months prior to the policy start.
RESULTS: Predicted future total spending for the chosen policy
option was within 1% of actual spending in the ﬁrst 11 months
($555.8M and $560.0M, respectively). The average difference
per week between actual and predicted amounts was 0.015%
($86,500, SD: $968,700). CONCLUSIONS: Such policy simu-
lation can be applied to a wide range of health plans and policy
changes.
PMC7
BRIDGING THE REQUIREMENT-CAPABILITY GAP BETWEEN
DRUG PLAN DECISION MAKERS AND THEIR DATA ANALYSTS
IN DRUG POLICY PLANNING
Burnett S1, Dormuth CR2, Schneeweiss SM2
1Pﬁa Corporation,Victoria, BC, Canada; 2Harvard University, Boston,
MA, USA
OBJECTIVES: Drug plan decision makers make choices of con-
siderable ﬁnancial impact in short periods of time. To reduce
